Evaluation of C-Reactive Protein and CXCL16 in Acute Coronary Syndrome

Abstract

Received 30/7/2019; Accepted 7/10/2019 DOI: 10.21608/ejrsa.2019.15472.1080 ©2019 National Information and Documentation Center (NIDOC) ACUTE coronary syndrome (ACS) is a life-threatening condition. Diagnosis and follow up depend on clinical examination, electrocardiogram (ECG), positron emission tomography (PET) and biochemical markers. Troponin is significantly used in the diagnosis and prognosis of ACS, however, its increase in absence of ACS prompts an evaluation for an alternative. CXCL16, an interferon γ regulated chemokine, in addition to the fact that it is expressed in atherosclerotic lesion. C-Reactive Protein (CRP) is up regulated in atheromatous plaque. The aim of the present study is to evaluate the importance of measurement of CRP and CXCL16 together with other biochemical markers of myocardial injury in the diagnosis and follow up of ACS.